Hepatitis B News and Research

Latest Hepatitis B News and Research

Democratic Sen. Harkin puts hold on Tavenner's nomination

Sen. Tom Harkin (D-Iowa) has placed a hold on one of President Obama's top healthcare nominees. Marilyn Tavenner had previously seemed poised for an easy, bipartisan confirmation as the administrator of the federal Medicare and Medicaid agency.

25 Apr 2013

Janssen submits Marketing Authorization Application to EMA for simeprevir approval

Medivir AB today announces that Janssen-Cilag International NV today has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval for simeprevir (TMC435).

25 Apr 2013

Dietary substitution of saturated fats enriched in MCT prevents liver disease

Scientists at the Arkansas Children's Nutrition Center, a U.S. Department of Agriculture Agricultural Research Service Human Nutrition Research Center at the University of Arkansas for Medical Sciences, led by Dr. Martin Ronis have determined that dietary substitution of saturated fats enriched in medium chain triglycerides (MCT) for polyunsaturated fat prevents the development of nonalcoholic fatty liver disease (NAFLD).

25 Apr 2013

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

A new drug is offering dramatic cure rates for hepatitis C patients with two subtypes of the infection -- genotype 2 and 3, say a team of scientists led by Weill Cornell Medical College researchers.

25 Apr 2013

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

Researchers at the University of Cincinnati have found that targeted screening for populations with a higher estimated prevalence for hepatitis C may be cost-effective.

25 Apr 2013

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen R&D Ireland today announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naive genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

24 Apr 2013

Home-based health education about diseases most effective, finds study

In the first study of its kind, lay health workers increased screening rates for hepatitis B virus (HBV) and knowledge about the disease among a group of Asian Americans, known as the Hmong, UC Davis researchers have found.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Medivir AB today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 hepatitis C patients.

23 Apr 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.

23 Apr 2013

DNAzymes, gold nanoparticles and disease detection: an interview with Dr Chan and Kyryl Zagorovsky, University of Toronto

Gold nanoparticles are tiny spherical particles made out of gold atoms with sizes on nanometre scale. This is around 1,000 times smaller than the thickness of human hair.

23 Apr 2013

Researchers decipher the underlying mechanism of antiviral drug

A long-forgotten candidate for antiviral therapy is undergoing a renaissance: Since the 1970s, the small molecule CMA has been considered a potent agent against viral infections, yet it was never approved for clinical use.

22 Apr 2013

Indian drug supplier cuts price of 5-in-1 childhood vaccine for GAVI Alliance; Groups highlight World Immunization Week

"The cost of immunizing children in developing countries with a five-in-one vaccine is set to fall after a deal by an Indian supplier to slash the price it charges the GAVI global vaccines group," Reuters reports.

19 Apr 2013

Ribavirin, interferon-alpha 2b inhibit virus replication in cell culture, NIH study finds

National Institutes of Health scientists studying an emerging coronavirus have found that a combination of two licensed antiviral drugs, ribavirin and interferon-alpha 2b, can stop the virus from replicating in laboratory-grown cells.

19 Apr 2013

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

RNAi-based therapeutics company Benitec Biopharma Limited today announced that the company's wholly owned US subsidiary, Tacere Therapeutics Inc., has submitted an application to the US National Institutes of Health's Recombinant DNA Advisory Committee.

18 Apr 2013

Flunisyn Phase 2a trial data shows positive results in elderly population

Following the widely publicised US Centers for Disease Control and Prevention report in February that the current season's flu vaccine is only 9% effective in the over-65 population, Immune Targeting Systems Limited, today announces positive data from a Phase 2a trial with the Company's lead pan-strain influenza A T-cell vaccine, Flunisyn, in the elderly population.

17 Apr 2013

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

RNAi-based therapeutics company Benitec Biopharma Limited today announced the selection of the University of California, San Diego, Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections.

16 Apr 2013

Hepatitis B News and Research

Latest Hepatitis B News and Research

Democratic Sen. Harkin puts hold on Tavenner's nomination

Janssen submits Marketing Authorization Application to EMA for simeprevir approval

Dietary substitution of saturated fats enriched in MCT prevents liver disease

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Home-based health education about diseases most effective, finds study

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

DNAzymes, gold nanoparticles and disease detection: an interview with Dr Chan and Kyryl Zagorovsky, University of Toronto

Researchers decipher the underlying mechanism of antiviral drug

Indian drug supplier cuts price of 5-in-1 childhood vaccine for GAVI Alliance; Groups highlight World Immunization Week

Ribavirin, interferon-alpha 2b inhibit virus replication in cell culture, NIH study finds

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

Flunisyn Phase 2a trial data shows positive results in elderly population

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Hepatitis B News and Research

Latest Hepatitis B News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in